William Franks will provide an overview on the two new oral treatments approved for use in Australia for COVID-19 – nirmatrelvir-ritonavir (Paxlovid) and molnupiravir (Lagevrio).
This will be followed by a panel discussion on the challenges and opportunities for pharmacists managing patients on COVID-19 disease modifying treatments with representation from various states.